宜明昂科-B收到AXION BIO的授权及合作协议项下里程碑付款

Core Viewpoint - The company has received a milestone payment of $10 million from Instil following the FDA approval for the initiation of Phase I clinical trials for IMM2510/AXN-2510 in the United States, indicating ongoing progress and commitment in their partnership [1] Group 1 - The total amount received under the licensing and collaboration agreement has reached $30 million, which includes the milestone payment [1] - The announcement reflects the strong collaboration and ongoing developments between the company and Instil [1]